Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

  |  

Susan Bernstein is a freelance journalist based in Atlanta.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. U.S. Food & Drug Administration. Drug approvals and databases: Drug trials dnapshots: RINVOQ. 2020 Jan 21.
  2. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. New Engl J Med. 2018 Mar 29;378(13):1200–1210.
  3. U.S. Food & Drug Administration. Drug safety and availability: FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR): FDA drug safety communication. 2019 Aug 28.
  4. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: Hitting the target. Nat Rev Rheumatol. 2015 May;11(5):290–300.
  5. Pottackal G, Travis J, Neuner R, et al. Application of bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States (abstract #2865). Arthritis Rheumatol. 2019 Oct;71(suppl 10).

Related Articles

    FDA Update: New Drug Approvals, New & Expanded Indications, & More

    ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

    As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…